Gsk GSK.GB | LONDON Exch | Medical-Diversified | MktCap p9.10T Sales p5.26T | Shares 5.084B Float 4.779B | EPS Due in 71 Days (e)

442080475000 gsk.com Middlesex, UNITED KINGDOM Inc 1999 MGMT owns --

EPS 18 x

EPS Rank 80

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom. LESS

ANNUAL - DEC END	2013	2014	2015	2016	2017	2018	2019	2020	2021
EPS GBX	112.50	57.30	174.30	18.80	31.40	73.73	93.90	115.54	87.65
CASH FLOW/SHR GBX	133.16	93.26	39.10	119.68	125.62	156.23	143.82	151.79	142.19
PRETAX MARGIN %	25%	13%	44%	7%	12%	16%	18%	20%	16%
RETURN ON EQUITY %	85%	65%	180%	29%	290%	169%	59%	44%	30%
SALES % CHANGE	0%	-13%	4%	17%	8%	2%	10%	1%	0%
SALES (MIL) GBX	3M	2M	2M	3M	3M	3M	3M	3M	3M
WEEKLY	**Mar 25**	**Apr 1**	**Apr 8**	**Apr 15**	**Apr 22**	**Apr 29**	**May 6**	**May 13**	**May 16**
DATAGRAPH RATING	67	69	68	68	68	76	76	76	76
AVG DAILY VOL (000)	9,231	8,785	8,704	8,898	9,037	9,055	9,047	9,099	9,076
UP DOWN VOLUME	0.9	1.0	1.2	1.2	1.0	1.1	1.1	1.1	1.1
ACCUM/DIST RATING	-5	2	33	23	13	17	7	3	3
RELATIVE STRENGTH	86	87	90	90	88	90	89	90	90
GROUP RANK	7	7	7	6	6	6	8	8	6

2022 Estimate		2023 Estimate	
121.59	39%	130.35	7%
Earnings Growth Rate		**Sales Growth Rate**	
2020-22 2% (17 Stability)		2%	
2018-22 32% (39 Stability)		4%	
COMP RATING 99		SMR RATING A	
INV T/O 2x 60			
DEBT % 2019-21	207%	161%	137%
TAX RATE 2019-21	16%	8%	6%
BACKLOG 2019-21	--	--	--
R & D 13.60%	BK VAL 5.39x '21		
DIV GBX 75.00 (4.9%)	DIV GR RT+0% (1)		
BETA 0.52(23.00)	ALPHA 0.09 (0.08)		
2021 EMPLOYEES 90,096 (-4%)			

Europe Long -0.93% in 2.9 WKS

OH -1% LOG (Fixed) PRICE

102.1 | 1,790 GBX | +34.80 +1.98%

90 C+

LOG VOLUME 40M 20M -12% 8.8M

FINANCIALS	Mar 18	Jun 18	Sep 18	Dec 18	Mar 19	Jun 19	Sep 19	Dec 19	Mar 20	Jun 20	Sep 20	Dec 20	Mar 21	Jun 21	Sep 21	Dec 21	Mar 22	Jun 22	Sep 22	Dec 22
EPS (GBX)	11.20	9.00	28.84	24.70	16.82	19.49	31.35	26.23	31.52	45.47	24.98	13.59	21.49	27.88	23.32	14.96	35.90	29.25e	37.96e	25.74e
EPS % CHANGE	-48%	+343%	+16%	+321%	+50%	+117%	+9%	+6%	+87%	+133%	-20%	-48%	-32%	-39%	-7%	+10%	+67%	+5%e	+63%e	+72%e
SALES (MIL GBX)	722,200.0	731,000.0	809,200.0	819,700.0	766,100.0	780,900.0	938,500.0	889,900.0	909,000.0	762,400.0	864,600.0				3.3M	952,700.0	978.0K	870.4Ke	957.7Ke	936.4Ke
SALES % CHANGE	-2%	0%	+3%	+7%	+6%	+7%	+16%	+9%	+19%	-2%	-8%				+285%				-71%e	-2%e
EPS % SURPRISE	+1.7%	+7.7%	+6.9%	+16.9%	+16.2%	+21.0%	+17.0%	-2.8%	+22.4%	-2.5%	+17.1%	+0.4%	+7.5%	+43.4%	+28.0%	+5.4%				
FUNDS	2,078	2,089	2,197	2,260	2,373	2,414	2,466	2,584	2,608	2,738	2,730	2,673	2,634	2,670	2,694	2,726	2,786			
SHARES HELD BY FUNDS	2B	2B	2B	2B	2B	2B	2B	2B	2B	2B	2B	2B	2B	2B	2B	2B	2B			

P/E	18
2022 Est.:	14.7
2023 Est.:	13.7
5-yr High:	67
5-yr Low:	11
vs Ind. Avg:	74.5x